Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01539941 · ClinicalTrials.gov registry record · Phase 1
Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD in Routine Care
A Phase 1 study, sponsored by The National Center on Addiction and Substance Abuse at Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01539941: Completed Phase 1 study, sponsored by The National Center on Addiction and Substance Abuse at Columbia University.
NCT01539941 is a Phase 1 study that has completed, run by The National Center on Addiction and Substance Abuse at Columbia University. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01539941, a Phase 1 study, has completed, sponsored by The National Center on Addiction and Substance Abuse at Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The goal of this proposal is to develop and pilot a brief protocol designed to systematically integrate pharmacological interventions for attention deficit hyperactivity disorder (ADHD) into behavioral treatment services for adolescent substance users with comorbid ADHD in everyday care. ADHD is a prevalent co-occurring condition for adolescent substance use (ASU) that can significantly impede successful ASU treatment but is vastly under-diagnosed and undertreated among ASU clients in agency settings. Moreover, ADHD medication acceptance and compliance is particularly difficult to achieve in high-risk adolescent populations.
Primary Outcome
Brief qualitative interviews will be designed and administered to the on-site psychiatrist and family therapists to capture judgments about the viability and acceptability of MIP compared to previous site practices, as well as its perceived short- and long-term safety and effectiveness for ASU/ADHD cases. A parallel qualitative interview will be administered to teens and caregivers at 3-month follow-up. MIP teens will also receive incentives to maintain medication diaries of daily pill intake, u
Interventions
- BEHAVIORAL Medication integration protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT01539941 record still lists
NCT01539941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Medication integration protocol is the first listed.
NCT01539941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01539941 about?
NCT01539941 is a clinical study titled "Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD in Routine Care". The goal of this proposal is to develop and pilot a brief protocol designed to systematically integrate pharmacological interventions for attention deficit hyperactivity disorder (ADHD) into behavioral treatment services for adolescent substance users with comorbid ADHD in everyday care. ADHD is a p...
What is the current status of trial NCT01539941?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-08. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01539941?
The interventions under investigation include: Medication integration protocol (BEHAVIORAL).
Who is sponsoring clinical trial NCT01539941?
This trial is sponsored by The National Center on Addiction and Substance Abuse at Columbia University, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01539941's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia